For the quarter ended December 2025, Sight Sciences, Inc. (SGHT Quick QuoteSGHT - Free Report) reported revenue of $20.39 million, up 6.9% over the same period last year. EPS came in at -$0.08, compared to -$0.23 in the year-ago quarter.

The reported revenue represents a surprise of +0.34% over the Zacks Consensus Estimate of $20.32 million. With the consensus EPS estimate being -$0.15, the EPS surprise was +44.83%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Sight Sciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Interventional Dry Eye: $0.72 million compared to the $0.6 million average estimate based on four analysts. The reported number represents a change of +138.2% year over year.
• Revenue- Interventional Glaucoma: $19.66 million compared to the $19.7 million average estimate based on four analysts. The reported number represents a change of +4.8% year over year.
• Gross Profit - Interventional Dry Eye: $0.5 million versus $0.3 million estimated by three analysts on average.
• Gross Profit - Interventional Glaucoma: $17.29 million versus $16.89 million estimated by three analysts on average.

View all Key Company Metrics for Sight Sciences here>>>

Shares of Sight Sciences have returned -18.7% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.